Showing results (151-160 of 1,945) with videos related to

Sort By:
Pageof 195
RMD Open|November 5, 2015
Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 studyMichael Schiff, Bernard Combe, Thomas Dörner, et al.
RMD Open|November 5, 2015
Socioeconomic inequities in perceived health among patients with musculoskeletal disorders compared with other chronic disorders: results from a cross-sectional Dutch studyP Putrik, S Ramiro, A M Chorus, et al.
RMD Open|November 5, 2015
Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritisMichael Nurmohamed, Yanjun Bao, James Signorovitch, et al.
RMD Open|November 5, 2015
Biosimilars: what do patients need to consider?Diana Skingle
RMD Open|January 29, 2016
Regulation of peripheral classical and non-classical monocytes on infliximab treatment in patients with rheumatoid arthritis and ankylosing spondylitisDaniel Aeberli, Richard Kamgang, Deepak Balani, et al.
RMD Open|January 29, 2016
Diagnostic impact of routine Lyme serology in recent-onset arthritis: results from the ESPOIR cohortDewi Guellec, Valérie Narbonne, Divi Cornec, et al.
RMD Open|January 29, 2016
A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remissionKaterina Chatzidionysiou, Carl Turesson, Annika Teleman, et al.
RMD Open|February 13, 2016
Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an exampleZhihong Lai, Anna La Noce
RMD Open|November 8, 2020
Hydroxychloroquine and the risk of respiratory infections among RA patientsJoel M Kremer, George Reed, Dimitrios A Pappas, et al.
RMD Open|November 8, 2020
Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to considerValentin Ritschl, Tanja A Stamm, Daniel Aletaha, et al.
Pageof 195